Patent · US Active

17β-hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions and methods of use thereof

US11180757B1 · kind B1 · utility

1Cited by

1References

30Claims

0Family size

Assignee

REGENERON PHARMACEUTICALS, INC. · US

Inventors

Gregory Hinkle · Plymouth, US
Frederic Tremblay · Boston, US
Noura S. Abul-Husn · New York, US
Omri GOTTESMAN · Sierra Sky Park, US
Alexander Li · White Plains, US
Xiping Cheng · Millwood, US
Yurong Xin · Tarrytown, US
Jesper Gromada · Scarsdale, US
Frederick Dewey · Winchester, US
Aris Baras · Tarrytown, US
Alan Shuldiner · Columbia, US
Stuart Milstein · Cambridge, US

Key dates

Filing date	May 14, 2021
Grant date	Nov 23, 2021
Priority date	—
Expiry date	May 14, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2320/50
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the HSD17B13 gene, as well as methods of inhibiting expression of HSD17B13, and methods of treating subjects that would benefit from reduction in expression of HSD17B13, such as subjects having a HSD17B13-associated disease, disorder, or condition, using such dsRNA compositions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.